List of Excipients in Branded Drug VASOTEC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	VASOTEC	enalapril maleate	0187-0140	LACTOSE
Bausch Health US LLC	VASOTEC	enalapril maleate	0187-0140	MAGNESIUM STEARATE
Bausch Health US LLC	VASOTEC	enalapril maleate	0187-0140	SODIUM BICARBONATE
Bausch Health US LLC	VASOTEC	enalapril maleate	0187-0140	SODIUM STEARATE
Bausch Health US LLC	VASOTEC	enalapril maleate	0187-0140	STARCH, CORN

Vasotec Excipient Strategy and Commercial Opportunities for Enalapril Maleate

Last updated: September 7, 2026

Vasotec is the original branded formulation of enalapril maleate, an angiotensin-converting enzyme inhibitor approved by the U.S. Food and Drug Administration in 1985 for hypertension and heart failure. Its core composition is relatively simple: enalapril maleate in an immediate-release tablet, with lactose, starch, magnesium stearate, and sodium bicarbonate identified as inactive ingredients in U.S. labeling.[1] The original compound and core tablet technology are no longer protected by meaningful U.S. market exclusivity. Commercial opportunity therefore lies in differentiated formulations, excipient substitution, pediatric delivery, adherence technologies, fixed-dose combinations, and regional regulatory positioning rather than in the legacy Vasotec brand.

What excipients are used in Vasotec tablets?

Vasotec tablets use conventional immediate-release excipients selected for manufacturability, tablet performance, and chemical stability.

Component	Functional role
Enalapril maleate	Active pharmaceutical ingredient
Lactose	Diluent and tablet massing agent
Starch	Filler, binder, and disintegrant
Magnesium stearate	Lubricant
Sodium bicarbonate	Alkalizing agent and possible stability aid

The formulation is not an extended-release, enteric-coated, orally disintegrating, or taste-masked system. The tablets are supplied in 2.5 mg, 5 mg, 10 mg, and 20 mg strengths in historical U.S. labeling.[1]

Why is sodium bicarbonate relevant?

Enalapril maleate is susceptible to hydrolytic conversion to enalaprilat. Moisture exposure, temperature, and microenvironmental pH can influence degradation. An alkaline excipient such as sodium bicarbonate can help control the local formulation environment and support chemical stability, although its precise contribution must be established through comparative stability studies rather than inferred from the ingredient list.

This creates a formulation-development opportunity. A generic or follow-on manufacturer may investigate alternative alkalizers, moisture scavengers, coatings, packaging systems, or granulation processes. Any replacement must preserve assay, related-substance limits, dissolution, content uniformity, tablet hardness, and long-term stability.

How does Vasotec’s formulation compare with generic enalapril?

Generic enalapril products can use different inactive ingredients while demonstrating pharmaceutical equivalence and bioequivalence. The FDA permits excipient variation when the finished product meets applicable quality and performance requirements.[2]

Attribute	Vasotec legacy tablet	Generic enalapril opportunity
Dosage form	Immediate-release tablet	Tablet, oral solution, or other approved presentation
Active ingredient	Enalapril maleate	Enalapril maleate, usually
Strengths	2.5, 5, 10, 20 mg	Commonly aligned with reference strengths
Core excipients	Lactose, starch, magnesium stearate, sodium bicarbonate	May use mannitol, microcrystalline cellulose, crospovidone, croscarmellose sodium, alternative lubricants, or other approved excipients
Release profile	Immediate release	Must match applicable performance requirements
Stability strategy	Conventional solid-dose approach	Opportunity for improved moisture protection and process robustness
Differentiation	Legacy brand	Pediatric, low-allergen, liquid, ODT, adherence, and combination products

The central commercial question is not whether an excipient is new. It is whether the excipient system reduces manufacturing cost, improves stability, addresses a patient need, or supports a defensible regulatory and intellectual-property position.

What excipient strategies create commercial opportunities for enalapril?

Lactose-free and low-allergen formulations

Lactose is widely used and generally economical, but some manufacturers and prescribers seek lactose-free products for patients with lactose intolerance, excipient sensitivities, or dietary restrictions. A formulation based on microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another suitable diluent could support a differentiated label.

The commercial value is limited in the standard adult tablet market because lactose-free substitution alone rarely justifies a large price premium. It can still support hospital tenders, country-specific procurement requirements, and specialty generic positioning.

Moisture-stable tablets

Enalapril formulations can be exposed to humidity during granulation, compression, packaging, and storage. A moisture-control platform could combine:

• Low-moisture excipients
• Dry granulation or direct compression
• Protective film coating
• High-barrier blister packaging
• Desiccant-containing bottles
• Optimized alkalizer concentration

The strongest commercial case would be a product with demonstrated stability in hot and humid markets, particularly where supply chains lack controlled temperature and humidity. This opportunity is more valuable outside the United States, where climatic-zone stability and packaging performance can affect product registration and procurement.

Orally disintegrating tablets

An orally disintegrating enalapril product could target patients with dysphagia, elderly patients, and those with reduced adherence to conventional tablets. Candidate excipients include mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and compressible sugar systems.

The main technical constraints are taste, mechanical strength, moisture sensitivity, and dose uniformity. Enalapril and enalaprilat can have an unpleasant taste profile, so a successful ODT would likely require taste masking through polymer coating, ion exchange, complexation, or coated microparticles. A simple faster-disintegrating tablet without taste control would have limited patient value.

Pediatric oral liquids

Pediatric enalapril is a clear formulation opportunity. Liquid products can improve dose flexibility for infants and children, but the formulation must manage hydrolysis, microbial control, palatability, sedimentation, and dosing-device accuracy.

Potential excipient categories include:

• Purified water as the vehicle
• Buffer or pH-adjusting systems
• Suspending agents for a suspension
• Preservatives where permitted
• Sweeteners and flavors
• Chelating agents or antioxidants where justified
• Syringe-compatible viscosity modifiers

An oral solution has a higher chemical-stability burden than a tablet because water accelerates hydrolysis. A suspension may provide better stability, but it requires redispersibility, dose uniformity, and shake-labeling controls. The FDA’s guidance on pediatric formulation development emphasizes age-appropriate excipient selection, palatability, dosing accuracy, and safety.[3]

A pediatric liquid supported by a clear stability profile and a dosing syringe could obtain stronger commercial differentiation than another conventional adult tablet.

What formulations are protected by potential new patents?

The legacy Vasotec tablet is unlikely to provide a meaningful basis for new patent protection. New filings would need to focus on formulation or process features that are novel, non-obvious, and adequately supported.

Potential claim areas include:

1. Stable aqueous enalapril formulations. Claims could cover pH, buffer ratios, preservative systems, chelators, packaging, and specified degradation limits.
2. Taste-masked enalapril particles. Claims could cover coating polymers, particle-size distributions, dissolution conditions, and taste-reduction performance.
3. Orally disintegrating tablets. Claims could focus on disintegration time, mechanical strength, excipient ratios, and stability.
4. Moisture-protective solid dosage forms. Claims could combine alkalizers, low-moisture excipients, coating systems, and barrier packaging.
5. Unit-dose or adherence packaging. Claims may cover calendar packs, dose counters, or integrated dispensing systems, although these are often easier to design around.
6. Fixed-dose combinations. Enalapril with hydrochlorothiazide is an established combination, so new patent value would require a distinct composition, release profile, stability improvement, or clinically meaningful use.

A formulation patent must be drafted around measurable technical performance. Broad claims covering enalapril plus ordinary pharmaceutical excipients would face substantial validity and written-description risk.

When did Vasotec lose exclusivity and what is its Orange Book status?

Vasotec’s core U.S. exclusivity ended decades ago. Enalapril maleate is a mature generic active ingredient, and generic manufacturers have long marketed enalapril tablets under abbreviated new drug applications.

The FDA Orange Book remains the controlling source for current reference-listed-drug status, patent listings, and exclusivity data.[4] For a mature product such as Vasotec, the practical market position is generally characterized by:

• No remaining original compound patent exclusivity
• No meaningful branded product exclusivity
• Multiple generic enalapril suppliers
• Price competition in standard tablet strengths
• Limited commercial protection from the historic Vasotec formulation

Any current patent risk would more likely arise from a later formulation, combination product, manufacturing process, or jurisdiction-specific right than from the original Vasotec tablet.

What generic entry risks exist for a new enalapril product?

A new entrant faces low scientific barriers but significant commercial barriers.

Regulatory risks

The principal regulatory risks are:

• Failure to establish bioequivalence
• Dissolution mismatch across strengths
• Enalapril-to-enalaprilat degradation
• Inadequate stability data
• Excipient safety concerns in pediatric populations
• Incomplete justification for a nonstandard dosage form
• Inadequate preservative effectiveness for liquids
• Poor dose uniformity in suspensions or multiparticulates

For an ANDA, the product generally must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. A substantially different dosage form, such as an oral solution or ODT, may require a different regulatory pathway or additional clinical and quality data depending on the product design.[2]

Commercial risks

The adult tablet market is commoditized. A product relying only on a different filler or lubricant would have limited pricing power. Buyers are likely to prioritize supply reliability, unit cost, quality history, and tender performance.

The most credible commercial niches are:

• Pediatric dosing
• Dysphagia and geriatric care
• Lactose-free products
• Hot-climate stability
• Hospital unit-dose packaging
• Combination therapy
• Markets with limited access to reliable liquid formulations

Which companies are challenging Vasotec?

The relevant competitive group is not a single challenger but the broad generic enalapril market. Generic manufacturers and distributors have marketed enalapril maleate tablets in the United States and internationally. The competitive set has included large multisource suppliers, regional manufacturers, and vertically integrated pharmaceutical companies.

The key competitive variables are:

Variable	Importance
Cost of API	High
Manufacturing yield	High
Stability and packaging	Medium to high
Regulatory history	High
Tender access	High
Pediatric or liquid capability	Medium
Patent differentiation	Low for standard tablets
Supply continuity	High

There is no biosimilar pathway for enalapril because it is a small-molecule drug, not a biologic. Competitive risk comes from generic substitution, not biosimilar entry.

What is the litigation and Paragraph IV risk?

The original Vasotec patents are too old to create a current core-product litigation strategy. Paragraph IV litigation is relevant only if a later patent is listed for a formulation, combination, method of use, or other qualifying product right.

For a new branded enalapril formulation, the owner could face Paragraph IV certification from generic applicants after patent listing. Risk would depend on:

• Whether the patent is listed in the Orange Book
• Claim scope
• Remaining patent term
• Number of potential generic entrants
• Whether the formulation is readily designed around
• Whether the product has meaningful clinical or commercial differentiation

A weak excipient patent covering routine substitutions would provide limited litigation leverage. A patent tied to a validated stability advantage, pediatric indication, or distinctive delivery system would be stronger.

How does enalapril compare with competing ACE inhibitors?

Enalapril competes with lisinopril, ramipril, captopril, perindopril, and other ACE inhibitors. Lisinopril has a simpler chemical profile because it is active as administered and does not require conversion from a prodrug. Enalapril’s formulation complexity is therefore higher, particularly for aqueous products.

Drug	Formulation implication	Excipient opportunity
Enalapril	Prodrug converted to enalaprilat; hydrolysis is a concern	Stability, pediatric liquid, taste masking
Lisinopril	Directly active; widely generic	Standard tablets and liquids
Captopril	Strong taste and oxidation concerns	Taste masking and antioxidant systems
Ramipril	Prodrug; low-dose formulation challenges	Content uniformity and stability
Perindopril	Prodrug; salt and stability considerations	Solid-state and moisture-control strategies

Enalapril’s best formulation opportunity is not a lower-cost copy of a conventional tablet. It is a stable, palatable, accurately dosed product for patients who cannot use standard tablets.

What licensing opportunities exist for Vasotec-related excipients?

Licensing opportunities are more likely to involve enabling technologies than the Vasotec brand itself. Potential partners include:

• Excipient suppliers with proprietary taste-masking systems
• Contract development and manufacturing organizations
• Pediatric formulation specialists
• High-barrier packaging companies
• Oral thin-film and ODT technology providers
• Regional pharmaceutical companies with tender access

A licensing transaction could be structured around a finished dosage form, a formulation platform, or territorial rights. The most defensible asset would combine formulation know-how, stability data, manufacturing scale-up, and regulatory support. An isolated excipient substitution would have limited licensing value unless it produced a measurable improvement in shelf life, palatability, or manufacturing economics.

What is the revenue exposure of a new Vasotec formulation?

Revenue exposure is concentrated in the generic adult market, where price erosion is predictable and entry barriers are low. Standard enalapril tablets are unlikely to support premium pricing without a specific procurement or patient-use advantage.

A differentiated product can improve economics through:

• Higher net price for pediatric or specialty presentations
• Lower wastage from extended shelf life
• Reduced packaging or manufacturing costs
• Preferred hospital formulary status
• Market access in countries with inadequate liquid supply
• Combination-product substitution
• Licensing fees or milestone payments

The highest-value opportunity is usually a platform with applications beyond enalapril. A pediatric liquid or taste-masking system that can be transferred to other cardiovascular drugs has greater strategic value than a single-drug reformulation.

Key Takeaways

• Vasotec is enalapril maleate, an old, highly genericized ACE inhibitor.
• The legacy tablet uses conventional excipients, including lactose, starch, magnesium stearate, and sodium bicarbonate.
• Core Vasotec exclusivity has expired, and standard tablets offer limited patent or pricing opportunity.
• The strongest excipient strategies involve moisture stability, pediatric liquids, taste masking, ODTs, lactose-free products, and high-barrier packaging.
• Enalapril is not exposed to biosimilar competition because it is a small molecule.
• New patent value would need to come from a specific formulation, process, stability result, delivery system, or method of use.
• The best commercial opportunity is a differentiated, regulator-ready product rather than another conventional immediate-release tablet.

FAQs

Can enalapril maleate be formulated as an oral solution?

Yes. An oral solution is technically feasible, but hydrolytic stability, preservative effectiveness, pH control, palatability, and in-use shelf life require focused development.

Is Vasotec still a protected branded product?

The original Vasotec tablet is not supported by meaningful current compound exclusivity. Current regulatory status should be assessed through the FDA Orange Book and active product labeling.

Which excipient is most important for enalapril stability?

No single excipient can be identified as universally decisive. Alkalizers, moisture control, packaging, and manufacturing conditions must be evaluated together through forced-degradation and long-term stability studies.

Does enalapril have biosimilar risk?

No. Enalapril is a chemically synthesized small molecule. Its competitive risk is generic substitution.

Can a new enalapril excipient formulation receive patent protection?

Yes, if the formulation provides a novel and non-obvious technical result, such as improved aqueous stability, taste masking, pediatric usability, or a distinct release profile.

References

1. Merck Sharp & Dohme LLC. (2017). Vasotec (enalapril maleate) tablets and injection prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2014). Regulatory guidance for industry: Use of inactive ingredients in approved drug products in pediatric patients. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.